Efficient Isolation of Antigen-Specific B Cells
Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at the forefront of vaccine research as scientists continue to develop new treatments to fight cancer, autoimmunity, and infectious disease. […]
Cancer Immunotherapy – High Precision & Remote-Controlled
Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating study on ultrasonic activation of cancer immunotherapy. CAR-T cell therapy is a paradigm shifting therapeutic with the potential to have an immense impact on cancer treatment options. The number of CAR-T therapies in clinical trial […]
NK cell therapy – Excellos Cells Aid Discovery of Key Cancer Killing Target
NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses Excellos sourced cellular starting materials for research on the mechanisms behind NK cell cytotoxicity. [1] The capacity for cancer cells to avoid immune detection is notorious. Normally, cells that are faulty, diseased, or reaching the […]
Allogeneic CAR-T Study – Healthy Donor Cells Outperform Patient Cells in Cancer Therapy
A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared to CAR-T cells derived from patients. [1] In a press release, biotechnology company Allogene Therapeutics announced preclinical results from their study on the treatment of multiple myeloma using allogeneic CAR-T cell therapy. Multiple myeloma is […]
Effective Solutions to Cell Therapy Supply Chain & Logistics
Where the Cell Therapy industry is facing an ever-growing complexity in supply chain and logistics, now is the time to optimize the cell therapy supply chain to create a dependable supply of cellular therapeutics. Adam Clark, Director of Commercial Operations here at Excellos recently attended the Supply Chain & Logistics for Cell Therapies Summit in […]
Cell Therapies – Building Solid Foundations for Success
Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are life sciences experts; both boast decades of experience at the forefront of biomedical research and technology. Mere […]
Part 2: Donor Immune Cell Characterization and Successful Cell Therapy
Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterization, and how those factors affect how well a patient may respond to immunotherapy. In Part 2 of […]
Part 1: High-Fidelity Donor Characterization and Successful Cell Therapy
TIL Therapy – Encouraging Results for Treating Metastatic Lung Cancer
Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cell therapies are some of the most promising cancer treatments developed in recent years to help fight aggressive cancers. […]
Anti-PD1 Cancer Treatment – Excellos T Cells Aid Evaluation
Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its role in regulating T cell activity. PD-1 and its analogs are often called “checkpoint inhibitors” because they act as a checkpoint to […]